XML 37 R21.htm IDEA: XBRL DOCUMENT v3.23.3
Insider Trading Arrangements
 3 Months Ended
Sep. 30, 2023
shares
Trading Arrangements, by Individual  
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
Deborah L. Weitzman [Member]  
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement During the three months ended September 30, 2023, Deborah L. Weitzman, Chief Executive Officer, Pharmaceutical Segment, adopted a Rule 10b5-1 sales plan. Adopted on August 28, 2023, Ms. Weitzman's plan provides for the sale of up to 9,000 common shares and the exercise of vested stock options and the associated sale of up to 27,642 common shares through November 15, 2024. The plan was adopted during an open trading window and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and our policies regarding insider transactions.
Name Deborah L. Weitzman
Title Chief Executive Officer, Pharmaceutical Segment
Rule 10b5-1 Arrangement Adopted true
Adoption Date August 28, 2023
Arrangement Duration 445 days
Deborah L. Weitzman Trading Arrangement, Common Stock [Member] | Deborah L. Weitzman [Member]  
Trading Arrangements, by Individual  
Aggregate Available 9,000
Deborah L. Weitzman Trading Arrangement, Stock Options [Member] | Deborah L. Weitzman [Member]  
Trading Arrangements, by Individual  
Aggregate Available 27,642